Second-Line NCCN Options and Approach to Progression

The segment introduces second-line sequencing, reviewing NCCN preferred options after frontline therapy.This segment reviews a FLAURA2 exploratory analysis on chemotherapy rechallenge and outlines a practical approach to progression. The discussion then addresses how the chemotherapy-free interval influences the decision to rechallenge with platinum/pemetrexed versus moving to an amivantamab-based regimen or datopotamab deruxtecan. The segment closes by differentiating between datopotamab deruxtecan and amivantamab plus chemotherapy in the subsequent-line setting, citing TROPION-Lung01 and TROPION-Lung05 data.